Archives
A Targeted Route to Higher Rabbit Pharming Yields
2026-11-14
A 2025 study tested whether placing a reporter transgene at the rabbit CSN2 milk-protein locus could raise recombinant protein concentrations in milk. The reported 15–20 g/L output in two homozygous animals is striking, but its interpretation is bounded by the small animal sample, cross-study comparisons, and the use of tdTomato rather than a therapeutic protein.
How CMC Shapes mRNA-LNP Translation
2026-11-13
A 2026 review explains why mRNA–lipid nanoparticle translation depends on more than delivery potency: lipid chemistry, particle attributes, physiological stability, analytical control, manufacturing comparability and regulatory precedent must be interpreted as one connected evidence chain.
Rabbit Pharming Through Targeted CSN2 Expression
2026-11-13
A literature-focused analysis of a 2025 rabbit pharming study shows how targeted insertion at the endogenous CSN2 locus produced heritable tdTomato expression and reported milk concentrations of 15–20 g/L in two homozygous females. The result is a promising proof of concept, but its interpretation is bounded by the reporter model, small animal number, historical rather than direct comparators, and the difference between concentration and total production.
What LNP Comparisons Really Establish for mRNA
2026-11-12
A source-grounded analysis of how lipid chemistry, carrier class, manufacturing strategy, and analytical controls shape interpretation of mRNA delivery evidence—and where published comparisons remain insufficient.
Why CSN2 Targeting Matters in Rabbit Pharming
2026-11-12
A 2025 study tested whether placing a reporter gene at the rabbit CSN2 milk-protein locus could overcome the variability of conventional transgenic pharming. The reported 15–20 g/L milk concentration in two homozygous animals is striking, but its broader significance is limited by the reporter construct, small production cohort, and lack of a controlled comparison with conventional lines.
How LNP Chemistry Shapes mRNA Translation
2026-11-11
A mechanistic interpretation of how lipid chemistry, particle attributes, and manufacturing controls influence the translation of mRNA delivery systems.
When Context Changes What a Result Means
2026-11-11
A result is not separable from the model, perturbation, readout and material context that produced it. Research on CCR7–Notch1 signaling in mammary cancer illustrates how genetic, pharmacological, cellular and database evidence support different levels of inference—and why heparin-affinity purification should not be mistaken for functional validation.
How LNP Chemistry Shapes mRNA Translation
2026-11-10
An evidence-led analysis of how lipid chemistry, particle attributes, manufacturing control, and physiological stability interact in mRNA delivery—and why these measurements should not be treated as interchangeable evidence of clinical performance.
How CSN2 Targeting Raised Rabbit Pharming Yields
2026-11-10
A 2025 study tested whether placing a reporter transgene at the endogenous CSN2 milk-protein locus could improve recombinant protein production in rabbits. Its high milk concentration is a compelling feasibility result, but the evidence remains limited by the reporter context, small number of high-yield animals, and the absence of a direct, controlled comparison isolating each design feature.
Cytosolic crRNAs: What the Evidence Shows
2026-11-09
A 2025 study found that U1 promoter-driven CRISPR RNAs improved several Cas13-based RNA-regulation readouts by favoring cytosolic availability, while also revealing important limits on what localization, reporter, and knockdown measurements can establish.
What Controls mRNA–LNP Translation?
2026-11-09
A literature-focused analysis of a 2026 review examining how lipid chemistry, critical quality attributes, manufacturing comparability, analytical strategy, and regulatory planning shape the translation of mRNA lipid nanoparticles. The review presents a CMC framework rather than a new controlled experiment, so its conclusions are strongest as an organizing model for evidence and risk, not as quantitative proof that one formulation or process is universally superior.
What mRNA-LNP CMC Evidence Can—and Cannot—Show
2026-11-08
A 2026 review explains how lipid chemistry, manufacturing controls, and analytical readouts shape mRNA nanoparticle translation. Those findings clarify delivery science, but they do not establish performance or compatibility for a serum-free cell-freezing medium.
Can CSN2 Knock-In Raise Rabbit Pharming Yields?
2026-11-07
A 2025 study reported unusually high milk concentrations of a fluorescent reporter in rabbits carrying a targeted insertion at the endogenous CSN2 locus. The result supports a proof of concept for promoter- and locus-directed expression, but cross-study comparisons remain limited because the benchmark lines, proteins, genetic backgrounds, and outcome measurements were not directly matched.
What a CSN2 Knock-In Rabbit Line Shows
2026-11-06
A 2025 study tested whether placing a reporter gene under the endogenous rabbit CSN2 milk-protein regulatory context could raise recombinant protein output. The reported 15–20 g/L tdTomato concentration in milk from two homozygous females is striking, but its interpretation is bounded by the small founder-derived dataset, cross-study comparator differences, and the use of a reporter rather than a therapeutic protein.
What CMC Decides in mRNA-LNP Translation
2026-11-06
A literature-focused analysis of how lipid chemistry, manufacturing control, analytical characterization, and comparability shape the translation of mRNA lipid nanoparticles from promising formulations to clinically and commercially credible products.